Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
With 70 clinical trials now underway on a “next generation” of more precisely targeted antibody drug conjugates, In Vivo profiles Ambrx and Sutro Biopharma, two smaller biotechs with promising technologies and powerful partners that augment their strong science with disease awareness, deep commercial networks and global geographic reach.
Oncology innovation: lots of drugs, lots of trials, sometimes not enough patients. And styles of innovation depend on whether a company has a big franchise to defend or would like one. In Vivo presents current data on sales, pipelines, trials and fails. (Free article.)
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.
Transparency is an issue that continues to pose reputational challenges for biopharma. A key flashpoint is the disclosure – under open access rules – of clinical trial data in a climate of mounting therapeutic competition. Still, some industry players are pushing the boundaries around open access. Project Data Sphere, a non-profit group backed by the CEO Roundtable on Cancer, is taking advantage of new IT platforms and the rich target potential in discovery science to press for a larger industry consensus around new ways to release high-value data embedded in years of trials, all for the benefit of cancer patients.
BTG's range of interventional oncology technologies puts it in an enviable position in R&D initiatives that require a holistic view across cancer and the best-targeted therapies. The UK-listed company will now take this to another level following an agreement with the Society of Interventional Oncology to explore the role of minimally invasive therapies in immuno-oncology.
Oncology drug development is undergoing rapid shifts. Bain research shows companies that seek to lead in speciﬁc vertical categories outperform rivals that invest across a broad spectrum of cancer targets.
ASCO’s 2017 annual meeting is expanding its focus on patient wellness beyond the clinic, with new research highlighting prevention, alternative treatments post-surgery, psycho-social factors and other issues reflecting the concerns of a growing new constituency of cancer survivors. In Vivo discusses this year’s agenda with ASCO’s CMO, Richard Schilsky.
Labeling, logistics and other issues were on the table as industry experts discussed the potential upcoming launches of CAR-T therapies in the US. Datamonitor Healthcare reported live from the ARM conference.
The pursuit by the industry to find novel combinations that can address more patients and more tumor types has driven overall immuno-oncology deal activity by big pharma and mid pharma companies between 2012 and 2016.
While reporting 19% US sales growth for the quarter, Lilly also outlined a revised oncology R&D strategy and revealed that refiling the NDA for baricitinib may be delayed 18 months or more.
Prior PD-1 failures after accelerated approval include Roche's Tecentriq in bladder cancer.
Impending critical data for AstraZeneca's PD-1 inhibitor Imfinzi, which is expected to be the backbone of the company's growing cancer immunotherapy portfolio, and speculation around CEO Pascal Soriot's recent trip to Israel, where it is rumored he met with a rival pharma company about its vacant chief exec role, will be hot topics during the company's second-quarter earnings call this week.
US FDA has approved the University of Virgina's plan to evaluate a therapy combining Theraclion's high intensity focused ultrasound with Merck's Keytruda (pembrolizumab) immunotherapy drug for the treatment of metastatic breast cancer.
ASCO 2017: Myriad's MyRisk; Nanobiotix' NBTXR3; Chronix' CNI Test; Sirtex SIR-Spheres; ANGLE’s Parsortix CTC Harvester
Over 30,000 oncologists and other health professionals attended the 2017 American Society of Clinical Oncology annual meeting in Chicago, June 2-6. This year's meeting included several presentations on emerging cancer diagnostic and device treatment strategies, including genetic tests, liquid biopsy systems, radioenhancers, and microspheres intended to improve chemotherapy outcomes.
Patients with HER2- metastatic breast cancer and who were tested positive for BRCA1/2 mutations with Myriad's BRACAnalysis CDx companion diagnostic showed they benefitted more from AstraZeneca's Lynparza (olaparib) than standard chemotherapy, according to results from a Phase III trial.
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.